Matthew Brink, MD
Glaucoma Specialist · Palm Beach Gardens, FLNPI 1598128829
Payments from drug & device makers
Across 528 payments — averaging $300.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sight Sciences, Inc.$89K
- Alcon Research LLC$23K
- Glaukos Corporation$16K
- AbbVie$8K
- Alcon$6K
- Bausch & Lomb Americas Inc.$5K
- plus $12K from 28 others
What the payments were for
- Consulting fees$50,15732%
- Speaking & faculty fees$71,14445%
- Travel & lodging$14,1059%
- Food & beverage$23,27915%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sight Sciences, Inc. | 122 | $89,106 |
| Alcon Research LLC | 14 | $23,183 |
| Glaukos Corporation | 35 | $15,964 |
| AbbVie(2 entities) | 88 | $7,866 |
| Alcon | 67 | $5,700 |
| Bausch & Lomb Americas Inc. | 35 | $4,675 |
| Dompe US, Inc. | 14 | $3,634 |
| NEW World Medical,inc. | 20 | $2,988 |
| Harrow Eye, LLC | 10 | $594 |
| Sun Pharmaceutical Industries Inc. | 12 | $474 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $422 |
| Mallinckrodt Hospital Products Inc. | 22 | $421 |
| Nova Eye, Inc. | 2 | $406 |
| Rayner Intraocular Lenses Limited | 10 | $395 |
| Novartis | 19 | $342 |
| Carl Zeiss Meditec USA, Inc. | 3 | $318 |
| Regeneron Healthcare Solutions, Inc. | 6 | $289 |
| Carl Zeiss Meditec, Inc. | 3 | $241 |
| Oyster Point Pharma, Inc. | 10 | $213 |
| Aerie Pharmaceuticals, Inc. | 5 | $211 |
| Rxsight Inc | 2 | $207 |
| Tarsus Pharmaceuticals, Inc. | 4 | $179 |
| Amgen | 3 | $159 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $147 |
| Biotissue Holdings Inc. | 2 | $128 |
| Kala Pharmaceuticals, Inc. | 5 | $100 |
| Topcon Healthcare, Inc. | 1 | $95 |
| Beaver-visitec International, Inc. | 1 | $73 |
| Astellas Pharma US Inc | 1 | $34 |
| Eyepoint US, Inc. | 1 | $33 |
| Dutch Ophthalmic, USA | 1 | $26 |
| Thea Pharma Inc. | 1 | $24 |
| Eyevance Pharmaceuticals LLC | 1 | $24 |
| Quidel Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OMNI(R) SURGICAL SYSTEM (US)$87,724
- SION SURGICAL INSTRUMENT$29,915
- iDose$10,810
- DURYSTA$4,220
- Oxervate$3,509
- Kahook Dual Blade$2,500
- Streamline Surgical System$2,500
- Ahmed Glaucoma Valve$2,500
- XEN GLAUCOMA TREATMENT SYSTEM$2,073
- iStent inject W$1,750
- VYZULTA$1,621
- SIMBRINZA$980
- LOTEMAX SM$699
- Centurion$650
- Wavelight Refractive Suite$650
- NGENUITY$605
- Hydrus Microstent$605
- iStent inject Trabecular Micro-Bypass System Model G2-M-IS$550
- AcrySof$490
- Clareon$391
How this compares
$158,685 in reported general payments places this provider in the 90th percentile of 31 glaucoma specialist providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 45 | $19,164 |
| RestasisCyclosporine | 13 | $15,751 |
| VyzultaLatanoprostene Bunod | 28 | $11,403 |
| RocklatanNetarsudil Mesylat/Latanoprost | 26 | $9,365 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 32 | $8,257 |
| Prednisolone Acetate | 142 | $4,621 |
| Travoprost | 37 | $4,373 |
| Latanoprost | 451 | $4,216 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 23 | $3,671 |
| Brimonidine Tartrate | 76 | $1,668 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 100 | $1,351 |
| Timolol Maleate | 84 | $1,201 |
| MoxifloxacinMoxifloxacin Hcl | 66 | $1,123 |
| Dorzolamide Hcl | 51 | $1,115 |
| Ketorolac Tromethamine | 62 | $914 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis | $7,866 | $34,91558 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $4,675 | $11,40328 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $211 | $9,36526 claims |
| AlconSimbrinza | $5,700 | $8,25732 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 31 glaucoma specialist providers in Florida.
Other glaucoma specialist in Palm Beach Gardens
- Steven VoldWinter Garden$2.5M
- Analisa ArosemenaMiami Beach$438K
- Yue WangMelbourne$92K
- David GreenfieldMiami$32K
- Mark WernerDelray Beach$24K
- Dan ArreazaHialeah$9K
- Daniel JewelewiczDelray Beach$9K
- Joah AliancyPort Orange$7K
- Phil AlabataCrestview$7K
- Clinton SheetsHudson$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.